OMER Jan 2025 12.000 call
OPR - OPR Delayed price. Currency in USD
Add to watchlist
As of 02:36PM EDT. Market open.
Loading interactive chart…
- GuruFocus.com
Omeros Corp (OMER) Q1 2024 Earnings Call Transcript Highlights: Financial Shifts and Strategic ...
Amidst a significant net loss increase, Omeros Corp navigates through promising drug trials and strategic royalty milestones.
- Business Wire
Omeros Corporation Reports First Quarter 2024 Financial Results
SEATTLE, May 15, 2024--Omeros Corporation (Nasdaq: OMER), a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders, today announced recent highlights and developments as well as financial results for the first quarter ended March 31, 2024, which include:
© 2024 Yahoo. All rights reserved.